Tandem jumps on FDA clearance of Tandem Mobi tubeless insulin pump

Windward Bio Group (WWB) surged 40% after a $225M IPO and $50M private placement. LifeMD (LFMD) gained 30% on Q3 results and partnerships. SS Innovations (SSII) rose 20% with new leadership. Tandem Diabetes (TNDM) advanced 14% on FDA clearance for a tubeless insulin pump.

Tandem Diabetes Care (TNDM) stock rose 14.2% after FDA clearance for its tubeless insulin delivery system, with a 2027 U.S. launch planned. Mizuho raised its price target to $20. Q3 2026 revenue was $283.7M, up 13.8% YoY, beating estimates. The move was driven by company-specific news, not broader market trends.

Tandem Diabetes Care (TNDM) shares rose 8% after FDA clearance for its tubeless Mobi insulin pump, which can operate for up to seven days. The pump maintains its advanced hybrid closed-loop technology and will launch commercially in early 2027. Existing pumps are compatible with the new tubeless components, and the company estimates pharmacy coverage reaches 50% of insured U.S. lives.

Tandem Diabetes Care received FDA clearance for a tubeless Tandem Mobi insulin pump option, cleared for 3-day cartridge and 7-day infusion set use. The system offers both tubed and tubeless options and retains Control-IQ+ technology. U.S. launch is planned for early 2027, according to the company.

TANDEM DIABETES CARE INC (TNDM) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On November 12, 2026, Tandem Diabetes Care, Inc. (the “Company”) received 510(k) clearance from the U.S. Food and Drug Administration for Tandem Mobi, the world’s first and only tubeless automated insulin delivery system with up to 7 days of wear (1) . A n

Tandem Diabetes Care (TNDM) received FDA clearance for its tubeless Mobi system, allowing up to 7 days of wear. The company plans a full U.S. commercial launch in the first half of 2027, with current pharmacy coverage at 50% of insured U.S. lives.